Erin Coglianese, MD
Cardiovascular Disease · Maywood, ILNPI 1063509107
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,125 of the $35,932 with a category attached, or 81.1%. Abbott accounts for 97.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $19,013 and has fallen 96.1% since, to $741 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $748.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$35K
- Abiomed$601
- Medtronic$274
Across 34 payments — averaging $14,863 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$458K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24K
- Abbott$23K
What the payments were for
- Consulting fees$29,12581%
- Speaking & faculty fees$4,00011%
- Travel & lodging$1,0383%
- Food & beverage$1,7695%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$19,870
- HeartMate 3 Left Ventricular Assist Device$9,488
- CARDIOMEMS$4,597
- ENSITE$595
- HeartWare HVAD$274
- ASSURITY$150
How this compares
$35,932 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 32 | $689,910 |
| EntrestoSacubitril/Valsartan | 148 | $178,324 |
| JardianceEmpagliflozin | 151 | $159,516 |
| EliquisApixaban | 75 | $85,404 |
| MounjaroTirzepatide | 14 | $14,808 |
| VascepaIcosapent Ethyl | 11 | $10,317 |
| Metoprolol Succinate | 112 | $2,198 |
| Atorvastatin Calcium | 73 | $1,614 |
| Ezetimibe | 33 | $1,591 |
| Warfarin Sodium | 71 | $1,378 |
| Eplerenone | 14 | $1,142 |
| Torsemide | 38 | $1,096 |
| Losartan Potassium | 57 | $1,000 |
| Rosuvastatin Calcium | 33 | $950 |
| Spironolactone | 95 | $646 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Maywood
- Niraj VarmaMaywood$522K
- Mark RabbatMaywood$363K
- Smit VasaiwalaMaywood$264K
- Clifford KavinskyMaywood$260K
- Gregory MacalusoMaywood$165K
- Dana JohnsonMaywood$104K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.